Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis

D. Basso, C. Fabris, M. Plebani, G. Del Favero, M. Muraca, M. T. Vilei, M. P. Panozzo, T. Meggiato, P. Fogar, A. Burlina, R. Naccarato

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This study was performed to investigate modifications in the serum bilirubin forms, hepatobiliary enzymes, and some glycoproteic substances in patients during the course of extrahepatic cholestasis (stage A) and following its clinical resolution (stage B). The series consisted of 16 patients 11 had main bile duct stones; two, benign stenosis of the main bile duct; and three, main bile duct cancer. Cholestasis resolved spontaneously in one case, under endoscopy in two, and following surgery in 13. Five patients with liver cirrhosis and a picture of intrahepatic cholestasis following anesthesia were also investigated. Serum bilirubin forms were measured using van den Bergh's method and the alkaline methanolysis-HPLC procedure; the mono- and di-conjugated forms were considered together in the overall evaluation of the results. The hepatobiliary enzymes (ALP, GGT, and AST) were increased at stage A and significantly decreased at stage B. Similar patterns were observed in total (TB), unconjugated (UB), and conjugated bilirubin (CB) and in the percentage of CB out of TB (% CB). In the majority of patients, % CB at stage B was lower than at stage, whereas in subjects with a high initial UB value, a different % CB pattern was observed. The direct bilirubin percentage (% DB), on the other hand, had a different pattern, and the variations between stages A and B were not significant. The pathophysiological bilirubin pattern was similar in patients with intrahepatic cholestasis. At stage A, in a number of patients the levels of glycoproteic substances (CA 19-9, TPA and ferritin) were raised, but at stage B they tended to decrease towards the normal range. Correlations were found between CA 19-9 or TPA variations and cholestasis indicators. It may be concluded that our HPLC technique may reveal differences in the behavior of the bilirubin pigments that cannot be detected with van den Bergh's method, even in the presence of similar TB variations. The increase in the glycoproteic substances considered may express an impairment in their metabolic (largely hepatic) clearance, as occurs in the cholestatic setting.

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalThe Clinical Investigator
Volume70
Issue number1
DOIs
Publication statusPublished - Jan 1992

Fingerprint

Extrahepatic Cholestasis
Intrahepatic Cholestasis
Bilirubin
Cholestasis
Bile Ducts
High Pressure Liquid Chromatography
Bile Duct Neoplasms
Enzymes
Ferritins
Serum
Liver Cirrhosis
Endoscopy
Pathologic Constriction
Reference Values
Anesthesia

Keywords

  • CA 19-9
  • Cholestasis
  • Ferritin
  • Serum bilirubins
  • TPA
  • Tumor markers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Basso, D., Fabris, C., Plebani, M., Del Favero, G., Muraca, M., Vilei, M. T., ... Naccarato, R. (1992). Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. The Clinical Investigator, 70(1), 49-54. https://doi.org/10.1007/BF00422939

Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. / Basso, D.; Fabris, C.; Plebani, M.; Del Favero, G.; Muraca, M.; Vilei, M. T.; Panozzo, M. P.; Meggiato, T.; Fogar, P.; Burlina, A.; Naccarato, R.

In: The Clinical Investigator, Vol. 70, No. 1, 01.1992, p. 49-54.

Research output: Contribution to journalArticle

Basso, D, Fabris, C, Plebani, M, Del Favero, G, Muraca, M, Vilei, MT, Panozzo, MP, Meggiato, T, Fogar, P, Burlina, A & Naccarato, R 1992, 'Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis', The Clinical Investigator, vol. 70, no. 1, pp. 49-54. https://doi.org/10.1007/BF00422939
Basso D, Fabris C, Plebani M, Del Favero G, Muraca M, Vilei MT et al. Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. The Clinical Investigator. 1992 Jan;70(1):49-54. https://doi.org/10.1007/BF00422939
Basso, D. ; Fabris, C. ; Plebani, M. ; Del Favero, G. ; Muraca, M. ; Vilei, M. T. ; Panozzo, M. P. ; Meggiato, T. ; Fogar, P. ; Burlina, A. ; Naccarato, R. / Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. In: The Clinical Investigator. 1992 ; Vol. 70, No. 1. pp. 49-54.
@article{401713e3e28e4c1b98825db840185546,
title = "Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis",
abstract = "This study was performed to investigate modifications in the serum bilirubin forms, hepatobiliary enzymes, and some glycoproteic substances in patients during the course of extrahepatic cholestasis (stage A) and following its clinical resolution (stage B). The series consisted of 16 patients 11 had main bile duct stones; two, benign stenosis of the main bile duct; and three, main bile duct cancer. Cholestasis resolved spontaneously in one case, under endoscopy in two, and following surgery in 13. Five patients with liver cirrhosis and a picture of intrahepatic cholestasis following anesthesia were also investigated. Serum bilirubin forms were measured using van den Bergh's method and the alkaline methanolysis-HPLC procedure; the mono- and di-conjugated forms were considered together in the overall evaluation of the results. The hepatobiliary enzymes (ALP, GGT, and AST) were increased at stage A and significantly decreased at stage B. Similar patterns were observed in total (TB), unconjugated (UB), and conjugated bilirubin (CB) and in the percentage of CB out of TB ({\%} CB). In the majority of patients, {\%} CB at stage B was lower than at stage, whereas in subjects with a high initial UB value, a different {\%} CB pattern was observed. The direct bilirubin percentage ({\%} DB), on the other hand, had a different pattern, and the variations between stages A and B were not significant. The pathophysiological bilirubin pattern was similar in patients with intrahepatic cholestasis. At stage A, in a number of patients the levels of glycoproteic substances (CA 19-9, TPA and ferritin) were raised, but at stage B they tended to decrease towards the normal range. Correlations were found between CA 19-9 or TPA variations and cholestasis indicators. It may be concluded that our HPLC technique may reveal differences in the behavior of the bilirubin pigments that cannot be detected with van den Bergh's method, even in the presence of similar TB variations. The increase in the glycoproteic substances considered may express an impairment in their metabolic (largely hepatic) clearance, as occurs in the cholestatic setting.",
keywords = "CA 19-9, Cholestasis, Ferritin, Serum bilirubins, TPA, Tumor markers",
author = "D. Basso and C. Fabris and M. Plebani and {Del Favero}, G. and M. Muraca and Vilei, {M. T.} and Panozzo, {M. P.} and T. Meggiato and P. Fogar and A. Burlina and R. Naccarato",
year = "1992",
month = "1",
doi = "10.1007/BF00422939",
language = "English",
volume = "70",
pages = "49--54",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis

AU - Basso, D.

AU - Fabris, C.

AU - Plebani, M.

AU - Del Favero, G.

AU - Muraca, M.

AU - Vilei, M. T.

AU - Panozzo, M. P.

AU - Meggiato, T.

AU - Fogar, P.

AU - Burlina, A.

AU - Naccarato, R.

PY - 1992/1

Y1 - 1992/1

N2 - This study was performed to investigate modifications in the serum bilirubin forms, hepatobiliary enzymes, and some glycoproteic substances in patients during the course of extrahepatic cholestasis (stage A) and following its clinical resolution (stage B). The series consisted of 16 patients 11 had main bile duct stones; two, benign stenosis of the main bile duct; and three, main bile duct cancer. Cholestasis resolved spontaneously in one case, under endoscopy in two, and following surgery in 13. Five patients with liver cirrhosis and a picture of intrahepatic cholestasis following anesthesia were also investigated. Serum bilirubin forms were measured using van den Bergh's method and the alkaline methanolysis-HPLC procedure; the mono- and di-conjugated forms were considered together in the overall evaluation of the results. The hepatobiliary enzymes (ALP, GGT, and AST) were increased at stage A and significantly decreased at stage B. Similar patterns were observed in total (TB), unconjugated (UB), and conjugated bilirubin (CB) and in the percentage of CB out of TB (% CB). In the majority of patients, % CB at stage B was lower than at stage, whereas in subjects with a high initial UB value, a different % CB pattern was observed. The direct bilirubin percentage (% DB), on the other hand, had a different pattern, and the variations between stages A and B were not significant. The pathophysiological bilirubin pattern was similar in patients with intrahepatic cholestasis. At stage A, in a number of patients the levels of glycoproteic substances (CA 19-9, TPA and ferritin) were raised, but at stage B they tended to decrease towards the normal range. Correlations were found between CA 19-9 or TPA variations and cholestasis indicators. It may be concluded that our HPLC technique may reveal differences in the behavior of the bilirubin pigments that cannot be detected with van den Bergh's method, even in the presence of similar TB variations. The increase in the glycoproteic substances considered may express an impairment in their metabolic (largely hepatic) clearance, as occurs in the cholestatic setting.

AB - This study was performed to investigate modifications in the serum bilirubin forms, hepatobiliary enzymes, and some glycoproteic substances in patients during the course of extrahepatic cholestasis (stage A) and following its clinical resolution (stage B). The series consisted of 16 patients 11 had main bile duct stones; two, benign stenosis of the main bile duct; and three, main bile duct cancer. Cholestasis resolved spontaneously in one case, under endoscopy in two, and following surgery in 13. Five patients with liver cirrhosis and a picture of intrahepatic cholestasis following anesthesia were also investigated. Serum bilirubin forms were measured using van den Bergh's method and the alkaline methanolysis-HPLC procedure; the mono- and di-conjugated forms were considered together in the overall evaluation of the results. The hepatobiliary enzymes (ALP, GGT, and AST) were increased at stage A and significantly decreased at stage B. Similar patterns were observed in total (TB), unconjugated (UB), and conjugated bilirubin (CB) and in the percentage of CB out of TB (% CB). In the majority of patients, % CB at stage B was lower than at stage, whereas in subjects with a high initial UB value, a different % CB pattern was observed. The direct bilirubin percentage (% DB), on the other hand, had a different pattern, and the variations between stages A and B were not significant. The pathophysiological bilirubin pattern was similar in patients with intrahepatic cholestasis. At stage A, in a number of patients the levels of glycoproteic substances (CA 19-9, TPA and ferritin) were raised, but at stage B they tended to decrease towards the normal range. Correlations were found between CA 19-9 or TPA variations and cholestasis indicators. It may be concluded that our HPLC technique may reveal differences in the behavior of the bilirubin pigments that cannot be detected with van den Bergh's method, even in the presence of similar TB variations. The increase in the glycoproteic substances considered may express an impairment in their metabolic (largely hepatic) clearance, as occurs in the cholestatic setting.

KW - CA 19-9

KW - Cholestasis

KW - Ferritin

KW - Serum bilirubins

KW - TPA

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0026545205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026545205&partnerID=8YFLogxK

U2 - 10.1007/BF00422939

DO - 10.1007/BF00422939

M3 - Article

C2 - 1600331

AN - SCOPUS:0026545205

VL - 70

SP - 49

EP - 54

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 1

ER -